Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial

This report has been verified by one or more authors of the original publication.

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

253 patients with primary knee osteoarthritis (OA) were randomized to receive a single intra-articular injection of either 6mL Hylan G-F 20 or saline placebo. The purpose of the study was to assess the efficacy of Hylan G-F 20 at reducing pain and improving knee function, as well as to assess the safety of its use. The primary outcome of interest was pain at 26 weeks after injection, as measured by the Western Ontario and McMaster Universities Osteoathritis Index pain subscale (WOMAC A). Secondary outcomes included pain subscores, functional scores (WOMAC C), and a safety analysis. Hylan G-F 20 demonstrated a significantly greater reduction in average pain over the 26 week follow-up from baseline when compared to the placebo group. Patient- and clinical observer global assessment of efficacy also significantly favoured the treatment group. Functional outcome and OMERACT-OARSI responder rate did not significantly differ between groups. Safety analysis demonstrated similar results for the two groups.